Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Appl Clin Med Phys. 2022 Jul;23(7):e13621. doi: 10.1002/acm2.13621. Epub 2022 Apr 21.
To evaluate the feasibility of a modified treatment strategy combined external beam radiation therapy (EBRT) and brachytherapy (BT) for cervical cancer through a dosimetry analysis.
This study retrospectively selected 12 cervical cancer patients treated with the conventional treatment strategy, which consisted of 45─50 Gy/25 fractions of EBRT using volumetric-modulated arc therapy (VMAT) and image-guided BT with a fraction dose of 5─7 Gy. The modified treatment strategy decreased the central EBRT dose while increasing the number of BT fractions. New target volumes were additionally contoured, and new VMAT EBRT plans were generated for the modified treatment strategy. The dosimetric parameters for evaluation included the doses to the most irradiated 2 cc (D2cc) of the organs at risk (OARs) and doses to at least 90% (D90) of the gross tumor volume (GTV) and high-risk clinical target volume (HR-CTV). The total doses to OARs and targets obtained by adding the equivalent doses in 2 Gy fraction (EQD2) from the EBRT and BT plans were used for quantitative comparison between the modified and conventional treatment strategies.
Comparison to the conventional treatment strategy, the modified treatment strategy resulted in a higher bladder D2cc, a slightly lower rectal D2cc and a similar HR-CTV D90, all with no significant differences (p > 0.05). The GTV D90 of the modified treatment strategy was significantly higher than that of the conventional treatment strategy (p < 0.01).
The modified treatment strategy can significantly increase the BT dose while remaining the total doses to the bladder and rectum basically unchanged, demonstrating its feasibility and promising prospect in clinical use.
通过剂量学分析,评估改良的外照射放射治疗(EBRT)联合近距离放射治疗(BT)治疗宫颈癌的可行性。
本研究回顾性选择了 12 例接受常规治疗策略的宫颈癌患者,该策略包括使用容积调强弧形治疗(VMAT)进行 45-50Gy/25 次分割的 EBRT,以及分割剂量为 5-7Gy 的图像引导 BT。改良治疗策略降低了中央 EBRT 剂量,同时增加了 BT 分割次数。此外,还对新的靶区进行了轮廓勾画,并为改良治疗策略生成了新的 VMAT EBRT 计划。评估的剂量学参数包括危及器官(OARs)的受照 2 立方厘米(D2cc)剂量、大体肿瘤体积(GTV)和高危临床靶区(HR-CTV)的至少 90%(D90)剂量。通过将 EBRT 和 BT 计划的等效剂量(EQD2)相加获得 OARs 和靶区的总剂量,用于改良和常规治疗策略之间的定量比较。
与常规治疗策略相比,改良治疗策略导致膀胱 D2cc 更高,直肠 D2cc 略低,HR-CTV D90 相似,均无统计学差异(p>0.05)。改良治疗策略的 GTV D90 明显高于常规治疗策略(p<0.01)。
改良治疗策略可以显著增加 BT 剂量,同时基本保持膀胱和直肠的总剂量不变,表明其在临床应用中具有可行性和广阔前景。